GLP-1 Side Effects Watch: Skin Blisters and Heart Rhythm Changes Explained

Q: What is bullous pemphigoid, and is it dangerous?

Bullous pemphigoid is an autoimmune blistering disease in which the immune system attacks the structural proteins that anchor the outer and inner layers of skin. It typically begins with intense itching and hive-like patches, then large, tense blisters that do not rupture easily. It is diagnosed with a skin biopsy and direct immunofluorescence, and it is treatable with anti-inflammatory and immunosuppressive therapy. It predominantly affects older adults and can become serious — mostly through skin breakdown, infection risk, and the burden of treatment — which is why new widespread blistering always warrants prompt medical evaluation, whether or not you take a GLP-1.

Q: Do GLP-1 medications cause atrial fibrillation or heart palpitations?

The evidence actually leans the other way. A 2026 umbrella review that appraised ten meta-analyses found pooled estimates suggesting GLP-1 receptor agonists are associated with LOWER rates of incident atrial fibrillation (odds ratios 0.54–0.83) and lower post-ablation AF recurrence (hazard ratios 0.58–0.78) (Ramzy et al., Cureus; PMID 42668799). However, the same review rated confidence in those pooled estimates as low or critically low using AMSTAR-2, and the underlying meta-analyses drew heavily on overlapping trials. So the honest summary is: no credible signal that GLP-1s cause AF, a plausible but uncertain protective association, and a firm rule that new palpitations or an irregular pulse should be evaluated clinically regardless.

Q: Should I stop my GLP-1 if I develop blisters or palpitations?

Do not stop on your own, but do contact your prescriber promptly — the same day for palpitations with chest discomfort, shortness of breath, dizziness, or fainting (call emergency services if severe), and within days for new itching or blistering. Bullous pemphigoid requires a dermatologist biopsy to diagnose; in published drug-associated cases, identifying and discontinuing the suspected trigger was part of management alongside treatment. For heart-rhythm symptoms, a clinician-ordered ECG — or a validated recording such as a smartwatch ECG reviewed by a clinician — can distinguish benign awareness of heartbeat from true arrhythmia (Isakadze et al.; PMID 31706789). Stopping abruptly without guidance risks rebound glucose and weight changes; a supervised decision is safer.

Q: How is drug-induced bullous pemphigoid diagnosed?

Diagnosis rests on three legs: the clinical picture (new widespread itching, hive-like plaques, or tense blisters, typically in older adults), a skin biopsy of the edge of a fresh blister, and direct immunofluorescence showing antibody deposition along the skin-layer junction. Attribution to a medication is a judgement call made after the diagnosis, using tools like the Naranjo probability scale and the timing of exposure — resolution after stopping the drug (dechallenge) and, rarely, recurrence after re-exposure (rechallenge) strengthen a causal claim. This is exactly why a single case report, without dechallenge and rechallenge data, cannot establish causation.

Skin Blisters on a GLP-1: What Bullous Pemphigoid Is

Bullous pemphigoid is an autoimmune disease in which the immune system attacks the protein anchors between the outer and deeper layers of the skin. The result is typically intense itching first — often mistaken for eczema or hives — followed by large, tense blisters that hold their fluid rather than rupture at a touch. It overwhelmingly affects older adults, it is confirmed by a skin biopsy with direct immunofluorescence, and it is treatable with anti-inflammatory and immunosuppressive regimens.

Why is it in the GLP-1 conversation? Because case reports have now tied the blistering picture to this drug class from more than one direction. The newest, from a team at Hospital Universitario 12 de Octubre in Madrid, describes tirzepatide as a possible trigger of bullous pemphigoid in a single patient (Hernández Madrid et al., JDDG 2026; PMID 42656044). It follows earlier reports with semaglutide (PMID 34466645) and dulaglutide (PMIDs 37822982, 31823494), and a 2024 review of rare cutaneous reactions to GLP-1 agonists catalogued the phenomenon while emphasizing the evidence base is case reports and small series (Salazar et al., Archives of Dermatological Research 2024; PMID 38795152; see also Burke et al., Skin Appendage Disorders 2025, PMID 41058954).

Drug-associated bullous pemphigoid is a recognized phenomenon beyond GLP-1s — other drug classes carry longer-documented associations. That precedent matters in both directions: it makes a GLP-1-triggered case biologically plausible, and it reminds us that millions of people have taken these medicines while the blistering reports remain countable case reports, not an epidemic.

Why One Case Report Does Not Prove Causation

A case report is a detailed story about one patient. It has enormous value: it alerts dermatologists to consider a medication when they see a specific picture, and it generates the hypotheses that later studies test. What it cannot do is tell you how often the event happens, because it has no denominator. One blistering case among millions of users and one blistering case among a thousand users look identical in a case report.

Timing is not causation, either. Bullous pemphigoid most often arises in older adults with no drug exposure at all; a patient who starts a GLP-1 and develops itching in the following months may be experiencing coincidence, a pre-existing autoimmune process unmasked by weight loss and medical attention, or a true drug reaction. Clinicians grade causality with structured criteria — probability scales, resolution after stopping the drug (dechallenge), and occasionally recurrence on re-exposure (rechallenge). The Madrid authors said exactly this when they titled their paper a “possible trigger.”

The patient version of that reasoning: a case report changes what you watch for, not what you expect. Watch for new persistent itching and tense blisters; expect to never see them.

Evidence type	What it is	What it can tell you
Case report	One (or a handful of) patient stories describing an event after a drug.	Generates hypotheses; no denominator, no comparison group, cannot estimate risk.
Pharmacovigilance analysis	Statistical screens of spontaneous adverse-event databases.	Detects signals; inflated by reporting bias and publicity.
Randomized controlled trial	Patients randomly assigned to drug or comparator, outcomes counted in both arms.	The workhorse for causation — but rare events need huge trials.
Meta-analysis	Pools results of many trials for more statistical power.	Only as good as the trials pooled — and reviews often reuse the same trials.
Umbrella review with appraisal	Reviews the meta-analyses themselves, rating methods and overlap.	The strongest lens on a messy literature — including honest confidence ratings.

GLP-1s and Atrial Fibrillation: What the Umbrella Review Found

The heart-rhythm story is almost the mirror image of the skin story. Multiple meta-analyses of randomized trials have reported that GLP-1 receptor agonists — semaglutide in particular — are associated with fewer new atrial fibrillation diagnoses and less AF recurrence after ablation (e.g., PMIDs 39058274, 36572913, 28569363). Those reviews appeared in such rapid succession, often re-using the same trials, that cardiologists at St. Joseph’s Regional Medical Center built an umbrella review to appraise the reviews themselves (Ramzy et al., Cureus 2026; PMID 42668799).

Their findings, in plain terms: across ten meta-analyses, pooled estimates for incident AF ranged from an odds ratio of 0.54 (95% CI 0.39–0.77) to 0.83 (95% CI 0.70–0.98) — every estimate on the favorable side of 1.0. For AF recurrence after ablation, hazard ratios ranged from 0.58 to 0.78, again favoring GLP-1 users. But the appraisal tempered the celebration: AMSTAR-2 ratings were low confidence for five reviews and critically low for four — none reached moderate or high confidence — and the corrected covered area showed the reviews drew heavily on overlapping trials (two recurrence reviews shared an identical six-study base yet pooled different numbers).

So the fairest summary a patient should take away: there is no credible evidence GLP-1s cause atrial fibrillation, there is a repeated — but methodologically fragile — association with less AF, and nobody should start a GLP-1 to treat a rhythm problem.

From Relative Odds to Real Numbers: Absolute Risk, Translated

“Odds ratio 0.83” is gibberish to most humans. Here is how to read it. An odds ratio of 0.83 means roughly 17% lower odds of the outcome compared with the comparator group. Whether that matters to you depends entirely on where you started — the baseline risk.

Take a clearly-labeled illustration. Imagine 100 people with a 4% chance of developing AF over the study period — 4 people. With an odds ratio of 0.83 (the least favorable pooled estimate in the umbrella review), about 3 of those 100 would develop AF instead: one fewer case per 100 people treated. With the most optimistic pooled estimate (0.54), it would be closer to 2 — about two fewer cases per 100. Those are modest, population-level differences, not personal guarantees; your own baseline risk depends on age, blood pressure, weight, alcohol, sleep apnea, and family history.

The same arithmetic discipline applied to the skin signal is why the right emotional register is awareness, not alarm: bullous pemphigoid case reports across GLP-1 agents total a handful of published patients against many millions of users. Rare does not mean imaginary — it means the right response is knowing the red flags, not losing sleep.

Key Terms

Bullous pemphigoid: An autoimmune blistering disease in which antibodies attack the anchors between skin layers, causing itching and tense blisters. Confirmed by biopsy; treatable.
Case report: A published description of a single patient (or a few). Valuable for generating hypotheses; incapable of measuring how often an event happens.
Dechallenge / rechallenge: Stopping a suspected drug to see if the problem resolves (dechallenge) and — rarely — re-exposing to see if it returns (rechallenge). The strongest clinical clues in drug-causality assessment.
Atrial fibrillation (AF): A rapid, irregular rhythm from the heart’s upper chambers. Common with age and obesity; raises stroke risk, which is why new irregular rhythms always warrant evaluation.
Odds ratio (OR): A relative measure comparing odds of an outcome between groups. Below 1.0 favors the treatment; 0.83 ≈ 17% lower odds.
Absolute vs relative risk: Relative measures tell you the direction and proportion of change; absolute risk tells you how many actual people are affected. Headlines trade in relative; decisions should use absolute.
Umbrella review: A review of multiple systematic reviews/meta-analyses, appraising their methods and overlap — the strongest lens on a crowded, recycled literature.
AMSTAR-2: A standard instrument for rating how much to trust a systematic review’s methods — the tool behind the “low confidence” ratings in the AF umbrella review.

Red-Flag Symptoms: When to Call Your Clinic

Safety signals only help patients when they convert into a concrete action plan. This is ours, and it doubles as a checklist you can bring to any prescriber — GLP-1 or otherwise.

Category	Symptoms to act on	Why
Skin — call your clinic within days	New, persistent itching without a clear cause; hive-like or eczema-like patches that spread; large, tense blisters filled with clear or blood-tinged fluid; blisters on normal-appearing skin; any blisters in the mouth, eyes, or genitals.	This pattern can be bullous pemphigoid or another serious drug eruption. It needs a dermatology look — often with a biopsy — before it progresses.
Heart — call your clinic the same day	Episodes of a racing, fluttering, or irregular pulse; pulse that feels chaotic when you check it; new exercise intolerance; unexplained dizziness.	Palpitations have many benign causes, but a first episode deserves documentation — an in-clinic ECG or a validated smartwatch tracing a clinician can read (Isakadze et al.; PMID 31706789).
Either — emergency care now	Chest pain or pressure; shortness of breath; fainting or near-fainting; blisters rapidly spreading across the body; fever with widespread blistering or skin sloughing.	These cross from "report it" to "get seen now" — call emergency services or go to the nearest emergency department.

One practical note on rhythm symptoms: a single-lead ECG from a modern smartwatch can capture an AF episode and give your clinician something actionable to read — a genuine triage advance, with real limits around sensitivity and interpretation (Isakadze et al., Trends in Cardiovascular Medicine 2020; PMID 31706789). Bring the recording; let a clinician make the call.

The Evidence at a Glance

Every claim on this page traces to one of these sources, rated by what each can actually support.

Study	What it examined	Key finding	What it means
Hernández Madrid 2026 — JDDG case report (PMID 42656044)	Single patient: tirzepatide flagged as a possible trigger of bullous pemphigoid.	Temporal association between tirzepatide exposure and new autoimmune blistering; authors explicitly frame it as "a possible trigger."	A hypothesis generator, not proof of a class effect. It tells dermatologists what to consider, not what to expect.
Salazar 2024 — Rare cutaneous reactions review (PMID 38795152)	Review of published literature on rare skin reactions to GLP-1 agonists.	Bullous pemphigoid and other serious skin reactions are documented almost entirely as case reports and small series.	Rare, real, and worth knowing — but incidence cannot be estimated from case reports.
Prior BP case reports — semaglutide & dulaglutide (PMIDs 34466645, 37822982, 31823494)	Individual case reports of bullous pemphigoid associated with semaglutide and dulaglutide.	Similar blistering picture reported across more than one GLP-1 agent.	Consistency across agents raises the question; it still does not establish incidence or causation.
Ramzy 2026 — Umbrella review of AF meta-analyses (PMID 42668799)	Appraised 10 meta-analyses (7 incident AF, 3 post-ablation recurrence) with AMSTAR-2 and overlap analysis.	Incident AF pooled odds ratios 0.54–0.83 (favoring GLP-1s); recurrence HRs 0.58–0.78 — but confidence rated low or critically low in 9 of 10 reviews, with substantial trial overlap.	The best current answer: no harm signal for AF, a plausible protective association of uncertain certainty.
Prior AF meta-analyses of RCTs (PMIDs 39058274, 36572913, 28569363)	Meta-analyses of randomized trials examining GLP-1 RAs and AF or cardiac arrhythmias.	Repeatedly reported lower incident AF rates with GLP-1 receptor agonists versus comparators.	The primary studies the umbrella review appraised — directionally consistent, individually limited.
Isakadze 2020 — Smartwatch ECG review (PMID 31706789)	Review of single-lead consumer ECG technology for arrhythmia detection.	Smartwatch ECGs can detect AF and generate clinically useful tracings when reviewed by a clinician.	A practical triage tool for palpitations — not a substitute for a physician-ordered ECG and evaluation.

The Safety Monitoring Protocol LuxeFit Follows

Step	What happens	Why it matters
Baseline skin and rhythm history	Document any existing eczema, psoriasis, autoimmune disease, or prior blistering; note baseline heart rhythm awareness and any AF history.	Case reports cannot be interpreted without knowing what was already there before the first dose.
Teach the red flags at day one	Every patient gets the skin and rhythm symptom list above, in writing, at the start of therapy.	Serious rare events are caught earlier by informed patients than by scheduled labs.
Same-day triage channel	A direct line for new blistering or palpitation symptoms, with a documented escalation path to dermatology or cardiology.	Case-report-level events are managed by specialists; the program’s job is to get you there fast.
Documentation for attribution	Symptom onset dates, dose-titration dates, and photos of skin findings stored in the chart.	Timing data are exactly what makes a possible drug association interpretable later.

What the Research Does Not Say

The evidence does not say that GLP-1s cause autoimmune blistering disease, and it does not say they protect your heart rhythm. The first claim outruns a handful of case reports; the second outruns pooled estimates whose methodological confidence the field’s own appraisal rated low. Both errors — panic and overconfidence — come from reading headlines at the wrong layer of the evidence hierarchy.

What the research does support is a quiet, practical posture: stay on therapy as prescribed, know the skin and rhythm red flags, use a same-day channel when they appear, and let specialists adjudicate. If a headline ever moves you to want to stop your medication, that is a conversation to have with your prescriber first — that is precisely what they are for.

Frequently Asked Questions

Can GLP-1 medications like Ozempic, Wegovy, or Zepbound cause skin blisters?

A 2026 case report in the Journal of the German Society of Dermatology described tirzepatide as a possible trigger of bullous pemphigoid (Hernández Madrid et al.; PMID 42656044), and similar reports exist for semaglutide (PMID 34466645) and dulaglutide (PMIDs 37822982, 31823494). These are temporal associations in individual patients — not proof of causation — and the condition remains rare among GLP-1 users. A 2024 review found the evidence limited to case reports and small series (Salazar et al.; PMID 38795152). Know the red flags (new persistent itching, then tense blisters) and report them promptly rather than stopping on your own.

What is bullous pemphigoid, and is it dangerous?

It is an autoimmune blistering disease: the immune system attacks the proteins anchoring the outer and deeper skin layers, causing intense itching and large, tense blisters, mostly in older adults. It is diagnosed by biopsy with direct immunofluorescence and is treatable. It can become serious through skin breakdown, infection risk, and treatment burden — which is why new widespread blistering always warrants prompt medical evaluation, regardless of medication.

Do GLP-1 medications cause atrial fibrillation or heart palpitations?

The evidence leans the other way. A 2026 umbrella review of ten meta-analyses found pooled odds ratios of 0.54–0.83 for incident AF and hazard ratios of 0.58–0.78 for post-ablation recurrence — all favoring GLP-1 users — while rating confidence in those estimates low or critically low and noting heavy overlap among the underlying trials (Ramzy et al.; PMID 42668799). So: no credible harm signal, a plausible but uncertain protective association, and new palpitations should still be evaluated clinically.

Should I stop my GLP-1 if I develop blisters or palpitations?

Do not stop on your own. For palpitations with chest discomfort, shortness of breath, dizziness, or fainting, seek same-day or emergency care. For new itching or blistering, contact your clinic within days — bullous pemphigoid requires a dermatologist and biopsy to diagnose, and in published drug-associated cases, stopping the suspected trigger was part of a supervised plan. A validated recording such as a smartwatch ECG can help document rhythm symptoms for your clinician (Isakadze et al.; PMID 31706789), but the stop/continue decision belongs to your prescriber.

How is drug-induced bullous pemphigoid diagnosed?

Three legs: the clinical picture (new widespread itching, hive-like plaques, or tense blisters, typically in older adults), a skin biopsy of a fresh blister, and direct immunofluorescence showing antibody deposition along the skin-layer junction. Attribution to a medication is judged afterwards using probability scales and timing — resolution after stopping the drug (dechallenge) and recurrence on re-exposure (rechallenge) strengthen causality. That is exactly why a single case report cannot establish causation.

References

PMID 42656044. Hernández Madrid P, Gotor Rivera A, Alejo Fernández-Baillo JL, Porres López E, Fulgencio Barbarin J. Tirzepatide as a possible trigger of bullous pemphigoid: A case report. Journal der Deutschen Dermatologischen Gesellschaft (JDDG), 2026. https://pubmed.ncbi.nlm.nih.gov/42656044/

PMID 42668799. Ramzy D, Isshak R, Patel D, Elmasry M, Shri N, Romero J, et al. Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, and Atrial Fibrillation: An Umbrella Review With Methodological Appraisal of Overlapping Meta-Analyses. Cureus, 2026;18(7):e113641. https://pubmed.ncbi.nlm.nih.gov/42668799/

PMID 38795152. Salazar CE, et al. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Archives of Dermatological Research, 2024. https://pubmed.ncbi.nlm.nih.gov/38795152/

PMID 34466645. Semaglutide-associated bullous pemphigoid. Case report, 2021. https://pubmed.ncbi.nlm.nih.gov/34466645/

PMID 37822982. Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature, 2023. https://pubmed.ncbi.nlm.nih.gov/37822982/

PMID 31823494. Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: A case report, 2019. https://pubmed.ncbi.nlm.nih.gov/31823494/

PMID 41058954. Burke OM, et al. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disorders, 2025. https://pubmed.ncbi.nlm.nih.gov/41058954/

PMID 39058274. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis, 2024. https://pubmed.ncbi.nlm.nih.gov/39058274/

PMID 36572913. Association of glucagon-like peptide-1 receptor agonists with cardiac arrhythmias in patients with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized controlled trials, 2023. https://pubmed.ncbi.nlm.nih.gov/36572913/

PMID 28569363. Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials, 2017. https://pubmed.ncbi.nlm.nih.gov/28569363/

PMID 31706789. Isakadze N, et al. How useful is the smartwatch ECG? Trends in Cardiovascular Medicine, 2020. https://pubmed.ncbi.nlm.nih.gov/31706789/

Turn Headlines Into a Plan, Not Panic

A licensed physician can review your skin and heart-rhythm history, give you the red-flag checklist in writing, and build a GLP-1 plan with a same-day channel for anything new.

Start a Consultation

LuxeFit Wellness is a patient management platform that partners with independent licensed physician networks to deliver medical services. LuxeFit Wellness does not directly provide medical or pharmacy services. Payment does not guarantee a prescription will be written or dispensed. Medical services are rendered by independent providers. Information on this website is for educational purposes only and does not replace professional medical advice. This website is an advertisement for services, not for any specific medication. Bullous pemphigoid and atrial fibrillation are rare or serious conditions; new blistering, palpitations with chest pain or shortness of breath, fainting, or sudden symptom progression warrants urgent or emergency medical evaluation. Nothing on this page establishes or excludes a causal relationship between any medication and any condition in any individual. Do not start, stop, or adjust any GLP-1 medication without consulting a licensed prescriber. Individual results vary and depend on dose, adherence, diet, exercise, and medical supervision.

Skin Blisters on a GLP-1: What Bullous Pemphigoid Is
Why One Case Report Does Not Prove Causation
GLP-1s and Atrial Fibrillation: What the Umbrella Review Found
From Relative Odds to Real Numbers: Absolute Risk, Translated
Red-Flag Symptoms: When to Call Your Clinic
The Evidence at a Glance
The Safety Monitoring Protocol LuxeFit Follows
What the Research Does Not Say
Frequently Asked Questions
References

Start Consultation